CAPRCapricor Therapeutics Inc

CSNasdaq (XNAS)·USD

Identity

Security key: 13096
Ticker: CAPR
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2002-06-20
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CAPR

Detail

Enriched 2026-08-14 20:47

Market cap: $242,650,831.67
Shares outstanding (class): 57,911,893
Shares outstanding (weighted): 57,911,893
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 231
Location: SAN DIEGO, CA
Homepage: https://www.capricor.com
Description: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Market cap and share counts drift.

Funds holding this security

76 funds · 77 positions · $162.75M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$44.51M	0.00%	1,464,205 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$35.63M	0.48%	1,171,894 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$32.33M	0.04%	1,063,418 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$15.63M	0.02%	514,086 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$10.82M	0.09%	356,045 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$3.34M	0.28%	109,901 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$2.15M	0.04%	70,821 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.98M	0.00%	64,983 NS	FIGI
JPMorgan U.S. Small Company Fund JPMorgan Trust I	—	$1.58M	0.17%	52,070 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$1.38M	0.04%	45,491 NS	FIGI
Fidelity Small Cap Growth Index Fund Fidelity Salem Street Trust	—	$1.01M	0.09%	33,131 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$818.9K	0.00%	26,939 NS	FIGI
LVIP SSGA Small-Cap Index Fund LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$796.5K	0.04%	26,200 NS	FIGI
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX… VANGUARD INSTITUTIONAL INDEX FUNDS	—	$675.8K	0.00%	22,230 NS	FIGI
EQ/Small Company Index Portfolio EQ Advisors Trust	—	$637.8K	0.04%	20,980 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCAPR
FIGI_COMPOSITEBBG000DZMK99
FIGI_SHARE_CLASSBBG001SKJV12
CIK0001133869
ISINUS14070B3096
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome therapies.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.